<DOC>
	<DOCNO>NCT01897961</DOCNO>
	<brief_summary>The Membranous nephropathy ( GEM ) idiopatic frequent cause syndrome n√©phrotique adult represent approximately 2 % cause terminal chronic renal insufficiency . A etiology balance assessment must systematically realize eliminate secondary cause . Antibodies manage receiver phospholipases A2 secrete type M ( PLA2R1 ) recently detect population GEM idiopatic , secondary GEM . PLA2R1 express podocytes glomerule healthy subject , receiver co-is locate deposit extramembraneous IgG expand subject idiopathique GEM . The good IgG extramembraneous depositsof GEM idiopathic recognize PLA2R1 . At patient , activity anti-PLA2R1 seem decrease disappear stake forgiveness disease . Some case second offense GEM idiopathique renal transplantation present antibody anti-PLA2R1 also describe . The appearance antibody anti-PLA2R1 seem parallel increase proteinurie touch second offense GEM , antibodies sometimes disappeared therapeutic strengthen Rituximab allow obtain forgiveness . A GEM also appear novo renal transplant , say without notion GEM native loin . The physiopathology affection remain unknown . Working hypothesis objective We shall look proportion presence antibody anti-PLA2R1 associate second offense GEM idiopathic renal transplantation . We anticipate GEM novo renal transplant answer different physiopathology , associate presence antibody anti-PLA2R1 . We hope demonstrate expand patient antibody anti-PLA2R1 , title antibody correlate activity disease renal survival , longitudinal follow-up title antibody interest forecast therapeutic .</brief_summary>
	<brief_title>Phospholipase A2 Receptor ( PLA2R1 ) Autoantibodies Membranous Nephropathy Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>Patients 18 year old , Presenting one follow three profile : Group 1 : patient whose renal disease origin GEM , 1a : must receive renal transplantation , transplant less three month day serum transplantation available laboratory immunology virology , 1b : transplant three month , do GEM yet , day serum transplantation available laboratory immunology virology . Group 2 : transplanted patient whose renal disease origin GEM , do GEM renal transplant , available serum day transplantation diagnosis second offense GEM laboratory immunology virology . Group 3 : transplanted patient , develop GEM novo , available serum day transplantation diagnosis GEM novo laboratory immunology virology . vulnerable person</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>